Syed Agha, MD
Interventional Cardiology · Cleveland, TNNPI 1164420741
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.0%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Cardiovascular Systems Inc. at 25.8% of the total. Reporting peaked in 2019 at $7,070 and has fallen 87.1% since, to $911 in 2025.
Across 514 payments — averaging $38.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$5K
- Medtronic$5K
- Abbott$2K
- Novartis$1K
- AstraZeneca$1K
- Boston Scientific$1K
- plus $4K from 28 others
What the payments were for
- Speaking & faculty fees$1,0005%
- Travel & lodging$8,46442%
- Food & beverage$10,37752%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 30 | $5,143 |
| Medtronic(2 entities) | 111 | $4,731 |
| Abbott | 61 | $2,304 |
| Novartis | 81 | $1,381 |
| AstraZeneca | 27 | $1,352 |
| Boston Scientific | 26 | $1,285 |
| Actelion Pharmaceuticals US, Inc. | 27 | $890 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 31 | $437 |
| E.r. Squibb & Sons, L.L.C. | 25 | $313 |
| Shockwave Medical, Inc | 7 | $294 |
| Johnson & Johnson | 16 | $280 |
| Amgen | 15 | $275 |
| Boehringer Ingelheim | 15 | $266 |
| Inari Medical, Inc. | 1 | $132 |
| Baxter Healthcare | 2 | $122 |
| Merck | 6 | $119 |
| Novo Nordisk | 5 | $88 |
| Pfizer | 5 | $87 |
| Scpharmaceuticals Inc. | 4 | $87 |
| Penumbra, Inc. | 3 | $53 |
| Chiesi USA, Inc. | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Abiomed | 1 | $22 |
| Cvrx, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $20 |
| Bayer | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Lantheus Medical Imaging, Inc. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Cashflow Solutions, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Peripheral Orbital Atherectomy System$4,111
- CoreValve Evolut$1,889
- AVEIR$1,320
- ClosureFast$1,020
- FARXIGA$1,000
- GENERAL VASCULAR ACCESS$765
- Coronary Orbital Atherectomy System$396
- Omnilink Elite vascular stent system$162
- FLOWTRIEVER CATHETER, S$132
- CT THROMBECTOMY SYSTEM KIT$132
- UPTRAVI$122
- OPSUMIT$122
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$118
- Abre$118
- Hillrom - Carnation Ambulatory Monitor$107
How this compares
$19,946 in reported general payments places this provider in the 75th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $168,175 |
| EntrestoSacubitril/Valsartan | 131 | $143,168 |
| XareltoRivaroxaban | 83 | $79,447 |
| JardianceEmpagliflozin | 77 | $61,619 |
| FarxigaDapagliflozin Propanediol | 42 | $39,173 |
| BrilintaTicagrelor | 28 | $19,005 |
| Repatha SureclickEvolocumab | 14 | $15,510 |
| Repatha SyringeEvolocumab | 16 | $9,752 |
| Ranolazine ErRanolazine | 18 | $4,591 |
| Metoprolol Succinate | 353 | $3,848 |
| Atorvastatin Calcium | 313 | $2,835 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 57 | $1,760 |
| Diltiazem 12hr ErDiltiazem Hcl | 11 | $1,719 |
| ClopidogrelClopidogrel Bisulfate | 158 | $1,394 |
| Flecainide Acetate | 25 | $1,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $87 | $168,175171 claims |
| NovartisEntresto | $1,381 | $143,168131 claims |
| Johnson & JohnsonXarelto | $280 | $79,44783 claims |
| Boehringer IngelheimJardiance | $266 | $61,61977 claims |
| AstraZenecaFarxiga, Brilinta | $1,352 | $58,17870 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Cleveland
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
- Brian JeffersonNashville$547K
- Malcolm FosterKnoxville$413K
- Mehul PatelGermantown$382K
- Michael MorseNashville$353K
- Nadia SuttonNashville$344K
- Ayaz RahmanKnoxville$251K
- Samuel HorrNashville$246K
- Joseph WeinsteinMemphis$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.